Cargando…

A non-natural nucleotide uses a specific pocket to selectively inhibit telomerase activity

Telomerase, a unique reverse transcriptase that specifically extends the ends of linear chromosomes, is up-regulated in the vast majority of cancer cells. Here, we show that an indole nucleotide analog, 5-methylcarboxyl-indolyl-2′-deoxyriboside 5′-triphosphate (5-MeCITP), functions as an inhibitor o...

Descripción completa

Detalles Bibliográficos
Autores principales: Hernandez-Sanchez, Wilnelly, Huang, Wei, Plucinsky, Brian, Garcia-Vazquez, Nelson, Robinson, Nathaniel J., Schiemann, William P., Berdis, Anthony J., Skordalakes, Emmanuel, Taylor, Derek J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469803/
https://www.ncbi.nlm.nih.gov/pubmed/30951520
http://dx.doi.org/10.1371/journal.pbio.3000204
_version_ 1783411683903930368
author Hernandez-Sanchez, Wilnelly
Huang, Wei
Plucinsky, Brian
Garcia-Vazquez, Nelson
Robinson, Nathaniel J.
Schiemann, William P.
Berdis, Anthony J.
Skordalakes, Emmanuel
Taylor, Derek J.
author_facet Hernandez-Sanchez, Wilnelly
Huang, Wei
Plucinsky, Brian
Garcia-Vazquez, Nelson
Robinson, Nathaniel J.
Schiemann, William P.
Berdis, Anthony J.
Skordalakes, Emmanuel
Taylor, Derek J.
author_sort Hernandez-Sanchez, Wilnelly
collection PubMed
description Telomerase, a unique reverse transcriptase that specifically extends the ends of linear chromosomes, is up-regulated in the vast majority of cancer cells. Here, we show that an indole nucleotide analog, 5-methylcarboxyl-indolyl-2′-deoxyriboside 5′-triphosphate (5-MeCITP), functions as an inhibitor of telomerase activity. The crystal structure of 5-MeCITP bound to the Tribolium castaneum telomerase reverse transcriptase reveals an atypical interaction, in which the nucleobase is flipped in the active site. In this orientation, the methoxy group of 5-MeCITP extends out of the canonical active site to interact with a telomerase-specific hydrophobic pocket formed by motifs 1 and 2 in the fingers domain and T-motif in the RNA-binding domain of the telomerase reverse transcriptase. In vitro data show that 5-MeCITP inhibits telomerase with a similar potency as the clinically administered nucleoside analog reverse transcriptase inhibitor azidothymidine (AZT). In addition, cell-based studies show that treatment with the cell-permeable nucleoside counterpart of 5-MeCITP leads to telomere shortening in telomerase-positive cancer cells, while resulting in significantly lower cytotoxic effects in telomerase-negative cell lines when compared with AZT treatment.
format Online
Article
Text
id pubmed-6469803
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-64698032019-05-03 A non-natural nucleotide uses a specific pocket to selectively inhibit telomerase activity Hernandez-Sanchez, Wilnelly Huang, Wei Plucinsky, Brian Garcia-Vazquez, Nelson Robinson, Nathaniel J. Schiemann, William P. Berdis, Anthony J. Skordalakes, Emmanuel Taylor, Derek J. PLoS Biol Research Article Telomerase, a unique reverse transcriptase that specifically extends the ends of linear chromosomes, is up-regulated in the vast majority of cancer cells. Here, we show that an indole nucleotide analog, 5-methylcarboxyl-indolyl-2′-deoxyriboside 5′-triphosphate (5-MeCITP), functions as an inhibitor of telomerase activity. The crystal structure of 5-MeCITP bound to the Tribolium castaneum telomerase reverse transcriptase reveals an atypical interaction, in which the nucleobase is flipped in the active site. In this orientation, the methoxy group of 5-MeCITP extends out of the canonical active site to interact with a telomerase-specific hydrophobic pocket formed by motifs 1 and 2 in the fingers domain and T-motif in the RNA-binding domain of the telomerase reverse transcriptase. In vitro data show that 5-MeCITP inhibits telomerase with a similar potency as the clinically administered nucleoside analog reverse transcriptase inhibitor azidothymidine (AZT). In addition, cell-based studies show that treatment with the cell-permeable nucleoside counterpart of 5-MeCITP leads to telomere shortening in telomerase-positive cancer cells, while resulting in significantly lower cytotoxic effects in telomerase-negative cell lines when compared with AZT treatment. Public Library of Science 2019-04-05 /pmc/articles/PMC6469803/ /pubmed/30951520 http://dx.doi.org/10.1371/journal.pbio.3000204 Text en © 2019 Hernandez-Sanchez et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Hernandez-Sanchez, Wilnelly
Huang, Wei
Plucinsky, Brian
Garcia-Vazquez, Nelson
Robinson, Nathaniel J.
Schiemann, William P.
Berdis, Anthony J.
Skordalakes, Emmanuel
Taylor, Derek J.
A non-natural nucleotide uses a specific pocket to selectively inhibit telomerase activity
title A non-natural nucleotide uses a specific pocket to selectively inhibit telomerase activity
title_full A non-natural nucleotide uses a specific pocket to selectively inhibit telomerase activity
title_fullStr A non-natural nucleotide uses a specific pocket to selectively inhibit telomerase activity
title_full_unstemmed A non-natural nucleotide uses a specific pocket to selectively inhibit telomerase activity
title_short A non-natural nucleotide uses a specific pocket to selectively inhibit telomerase activity
title_sort non-natural nucleotide uses a specific pocket to selectively inhibit telomerase activity
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469803/
https://www.ncbi.nlm.nih.gov/pubmed/30951520
http://dx.doi.org/10.1371/journal.pbio.3000204
work_keys_str_mv AT hernandezsanchezwilnelly anonnaturalnucleotideusesaspecificpockettoselectivelyinhibittelomeraseactivity
AT huangwei anonnaturalnucleotideusesaspecificpockettoselectivelyinhibittelomeraseactivity
AT plucinskybrian anonnaturalnucleotideusesaspecificpockettoselectivelyinhibittelomeraseactivity
AT garciavazqueznelson anonnaturalnucleotideusesaspecificpockettoselectivelyinhibittelomeraseactivity
AT robinsonnathanielj anonnaturalnucleotideusesaspecificpockettoselectivelyinhibittelomeraseactivity
AT schiemannwilliamp anonnaturalnucleotideusesaspecificpockettoselectivelyinhibittelomeraseactivity
AT berdisanthonyj anonnaturalnucleotideusesaspecificpockettoselectivelyinhibittelomeraseactivity
AT skordalakesemmanuel anonnaturalnucleotideusesaspecificpockettoselectivelyinhibittelomeraseactivity
AT taylorderekj anonnaturalnucleotideusesaspecificpockettoselectivelyinhibittelomeraseactivity
AT hernandezsanchezwilnelly nonnaturalnucleotideusesaspecificpockettoselectivelyinhibittelomeraseactivity
AT huangwei nonnaturalnucleotideusesaspecificpockettoselectivelyinhibittelomeraseactivity
AT plucinskybrian nonnaturalnucleotideusesaspecificpockettoselectivelyinhibittelomeraseactivity
AT garciavazqueznelson nonnaturalnucleotideusesaspecificpockettoselectivelyinhibittelomeraseactivity
AT robinsonnathanielj nonnaturalnucleotideusesaspecificpockettoselectivelyinhibittelomeraseactivity
AT schiemannwilliamp nonnaturalnucleotideusesaspecificpockettoselectivelyinhibittelomeraseactivity
AT berdisanthonyj nonnaturalnucleotideusesaspecificpockettoselectivelyinhibittelomeraseactivity
AT skordalakesemmanuel nonnaturalnucleotideusesaspecificpockettoselectivelyinhibittelomeraseactivity
AT taylorderekj nonnaturalnucleotideusesaspecificpockettoselectivelyinhibittelomeraseactivity